title: Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.
abstract: In this study we have evaluated the modifications of matrix metalloproteinases (MMPs) in malignant pleural fluids taken from patients suffering from lung cancer and treated with intrapleural talc instillation to induce pleurodesis. Furthermore, we have analysed the variations of some inflammatory mediators (C-reactive protein, alpha-1 antitrypsin) and of a protein (plasminogen) involved in MMP activation. In all patients the clinical improvement after talc pleurodesis was followed by a reduction in MMP-1, TIMP-1, C-reactive protein, alpha-1 antitrypsin and plasminogen activity. Furthermore, MMP-9 levels were variable; in fact, in some patients they were high at the beginning of treatment, in others they increased a few days after pleurodesis induction. These inhibitory effects of talc on MMP-1 and inflammatory mediators associated with the reduction of pleural effusion could constitute an effective means to evaluate the evolution of the treatment.
authors.affiliation: Azienda Ospedaliera-Universitaria Policlinico, University of Palermo, Palermo, Italy.
authors.forename: P
authors.initials: P
authors.lastname: D'Agostino
authors.forename: A Rao
authors.initials: AR
authors.lastname: Camemi
authors.forename: R
authors.initials: R
authors.lastname: Caruso
authors.forename: F
authors.initials: F
authors.lastname: Arcoleo
authors.forename: A
authors.initials: A
authors.lastname: Cascio
authors.forename: A
authors.initials: A
authors.lastname: Dolce
authors.forename: E
authors.initials: E
authors.lastname: Sacco
authors.forename: G
authors.initials: G
authors.lastname: Cangemi
authors.forename: T
authors.initials: T
authors.lastname: di Rosa
authors.forename: P
authors.initials: P
authors.lastname: Moceo
authors.forename: E
authors.initials: E
authors.lastname: Cillari
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000032:analysis / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000032:analysis / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis / Q000378:metabolism; D016066:Pleural Effusion, Malignant / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D018700:Pleurodesis; D018709:Statistics, Nonparametric; D013627:Talc / Q000008:administration & dosage*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000032:analysis / Q000378:metabolism
chemical_list: D019715:Tissue Inhibitor of Metalloproteinase-1; D000515:alpha 1-Antitrypsin; D013627:Talc; D010958:Plasminogen; D002097:C-Reactive Protein; D020782:Matrix Metalloproteinases; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1